Literature DB >> 22960958

Default from neoadjuvant chemotherapy in premenopausal female breast cancer patients: what is to blame?

O A Egwuonwu1, S N C Anyanwu, A M E Nwofor.   

Abstract

BACKGROUND: Breast cancer is the most frequent cancer among women in most parts of the world including Nigeria. Neoadjuvant chemotherapy has been demonstrated to be a helpful strategy in the context of locally advanced breast cancer. AIMS: The purpose of this study was to investigate some factors that may contribute to low rate of acceptance and adherence to neoadjuvant chemotherapy.
MATERIALS AND METHODS: A 1-year prospective study of premenopausal women with locally advanced breast cancer recommended for neoadjuvant chemotherapy from June 2009 to May 2010.
RESULTS: Forty-four patients gave consent to be part of the study. The ages ranged from 26 to 51 years with a mean age of 42.1 years ± 7.7 years. Only 31 patients completed the four courses of NAC. Seventeen (38.6%) patients dropped out of treatment, before, during or after completing NAC. Ten of these defaulted due to inadequate funds to procure chemotherapy, three patients because they insisted on immediate mastectomy, and four of these patients refused surgery when they achieved complete clinical response, probably due to fear of mastectomy which is common among women in our environment. Twenty patients had dose deferment.
CONCLUSION: Lack of funds to procure chemotherapy and refusal of additional modality of treatment are the two major factors responsible for default of NAC and its goal in patients with LABC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960958     DOI: 10.4103/1119-3077.100618

Source DB:  PubMed          Journal:  Niger J Clin Pract            Impact factor:   0.968


  3 in total

1.  African Breast Cancer-Disparities in Outcomes (ABC-DO): protocol of a multicountry mobile health prospective study of breast cancer survival in sub-Saharan Africa.

Authors:  Fiona McKenzie; Annelle Zietsman; Moses Galukande; Angelica Anele; Charles Adisa; Herbert Cubasch; Groesbeck Parham; Benjamin O Anderson; Behnoush Abedi-Ardekani; Joachim Schuz; Isabel Dos Santos Silva; Valerie McCormack
Journal:  BMJ Open       Date:  2016-08-23       Impact factor: 2.692

2.  ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol.

Authors:  Atara I Ntekim; Abiola Ibraheem; Adenike A Sofoluwe; Olayinka Kotila; Chinedum Babalola; Theodore Karrison; Christopher O Olopade
Journal:  JCO Glob Oncol       Date:  2020-07

3.  Quality of Breast Cancer Treatment at a Rural Cancer Center in Rwanda.

Authors:  Daniel S O'Neil; Nancy L Keating; Jean Marie V Dusengimana; Vedaste Hategekimana; Aline Umwizera; Tharcisse Mpunga; Lawrence N Shulman; Lydia E Pace
Journal:  J Glob Oncol       Date:  2017-05-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.